Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Quest Diagnostics    DGX

QUEST DIAGNOSTICS

(DGX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Studies from Quest Diagnostics Yield New Information about Chronic Lymphocytic Leukemia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/31/2019 | 05:00pm EST

By a News Reporter-Staff News Editor at Cancer Weekly -- Data detailed on Oncology - Chronic Lymphocytic Leukemia have been presented. According to news reporting originating from Marlborough, Massachusetts, by NewsRx correspondents, research stated, "The prognostic role of cytogenetic analysis is well-established in B-cell chronic lymphocytic leukemia (CLL). Approximately 80% of patients have a cytogenetic aberration."

Our news editors obtained a quote from the research from Quest Diagnostics, "Interphase FISH panels have been the gold standard for cytogenetic evaluation, but conventional cytogenetics allows detection of additional abnormalities, including translocations, complex karyotypes and multiple clones. Whole genome copy number assessment, currently performed by chromosomal microarray analysis (CMA), is particularly relevant in CLL for the following reasons: (1) copy number alterations (CNAs) represent key events with biologic and prognostic significance; (2) DNA from fresh samples is generally available; and (3) the tumor burden tends to be relatively high in peripheral blood. CMA also identifies novel copy number variants and copy-neutral loss-of-heterozygosity (CN-LOH), and can refine deletion breakpoints. The Cancer Genomics Consortium (CGC) Working Group for CLL has performed an extensive literature review to describe the evidence-based clinical utility of CMA in CLL."

According to the news editors, the research concluded: "We provide suggestions for the integration of CMA into clinical use and list recurrent copy number alterations, regions of CN-LOH and mutated genes to aid in interpretation."

For more information on this research see: Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Cancer Genetics, 2018;228-229():236-250. Cancer Genetics can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Cancer Genetics - www.journals.elsevier.com/cancer-genetics/)

The news editors report that additional information may be obtained by contacting P.M. Miron, Quest Diagnost, Marlborough, MA 01752, United States. Additional authors for this research include G.D. Wenger, A. Chaubey, D.P. Dash, R. Kanagal-Shamanna, S. Kantarci, R. Kolhe, D.L. Van Dyke, L. Wang, D.J. Wolff and K. Chun (see also Oncology - Chronic Lymphocytic Leukemia).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.cancergen.2018.07.004. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright 2019, NewsRx LLC, source Health Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
CANCER GENETICS INC 3.19% 0.259 Delayed Quote.7.02%
QUEST DIAGNOSTICS 2.70% 87.81 Delayed Quote.2.68%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on QUEST DIAGNOSTICS
02/14QUEST DIAGNOSTICS : 4Q Earnings Snapshot
AQ
02/14QUEST DIAGNOSTICS INC : Results of Operations and Financial Condition, Financial..
AQ
02/14QUEST DIAGNOSTICS : Reports Fourth Quarter And Full Year 2018 Financial Results;..
PR
02/11QUEST DIAGNOSTICS : Completes Acquisition of Laboratory Services Business of Boy..
PR
01/22QUEST DIAGNOSTICS : Named One of 2019 "World's Most Admired Companies" by Fortun..
PR
01/14QUEST DIAGNOSTICS : More Adults Know Their Multidigit Wi-Fi Password Than Vital ..
PR
01/14QUEST DIAGNOSTICS : Ex-dividend day for
FA
01/07QUEST DIAGNOSTICS : To Release Fourth Quarter And Full Year 2018 Financial Resul..
PR
01/02QUEST DIAGNOSTICS : To Speak At The 37th Annual J.P. Morgan Healthcare Conferenc..
PR
01/02QUEST DIAGNOSTICS : New Study Shows That You Are Probably High On Drugs At Your ..
AQ
More news
Financials ($)
Sales 2019 7 708 M
EBIT 2019 1 252 M
Net income 2019 787 M
Debt 2019 3 434 M
Yield 2019 2,36%
P/E ratio 2019 14,93
P/E ratio 2020 14,18
EV / Sales 2019 2,00x
EV / Sales 2020 1,94x
Capitalization 11 948 M
Chart QUEST DIAGNOSTICS
Duration : Period :
Quest Diagnostics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUEST DIAGNOSTICS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 95,5 $
Spread / Average Target 8,7%
EPS Revisions
Managers
NameTitle
Stephen H. Rusckowski Chairman, President & Chief Executive Officer
Mark J. Guinan Chief Financial Officer & Executive Vice President
Lidia L. Fonseca Chief Information Officer & Senior Vice President
Jay G. Wohlgemuth Chief Medical Officer, Senior VP-R&D, Medical
Gail R. Wilensky Independent Director
Sector and Competitors